Skye Bioscience (SKYE) Stock: Buy, Sell, or Hold?
SKYE - Skye Bioscience, Inc. Common Stock
$1.54
-0.08 (-4.94%)
▼
5d:
-0.65%
30d:
-9.41%
90d:
+147.27%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
15d
Get Alerted When SKYE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SKYE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SKYE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SKYE is currently trading at $1.54, which is considered oversold relative to its 30-day fair value range of $1.54 to $1.77.
Technical Outlook: Technically, SKYE is in a strong uptrend. The price is currently testing key support at $1.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: SKYE scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $68.00 (+4315.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SKYE is in a strong uptrend. The price is currently testing key support at $1.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: SKYE scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $68.00 (+4315.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.54 -
$1.77
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 4315.6% below Wall St target ($68.00)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.54 -
$1.77
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.50
Resistance Level
$1.70
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.21
Wall Street Target
$68.00
(+4315.6%)
Share & Embed Analysis
Last updated: October 24, 2026 2:38 PM ET
Data refreshes hourly during market hours. Next update: 3:38 PM
Data refreshes hourly during market hours. Next update: 3:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SKYE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 66 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
